secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2025-06-04T23:59:59+00:00
Accession:  0001171843-25-003661
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus soquelitinib Phase 1 atopic dermatitis data show statistically significant EASI improvement vs placebo
--------------------------------------------------------------------------------

- Soquelitinib met primary endpoint with statistically significant EASI improvement vs placebo at day 28 (p=0.036).
- Cohort 3 (200 mg BID) achieved 64.8% mean EASI reduction vs 34.4% for placebo.
- In cohort 3, 50% of evaluable patients (4/8) had a ≥4-point itch reduction (PP-NRS) at day 28.
- No safety signals; soquelitinib well tolerated with no DLTs and only one grade 1 AE (nausea).
- Extension cohort (200 mg BID, 8-week treatment) enrollment has been initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184325003661/0001171843-25-003661-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184325003661/f8k_060425.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-003661

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer